
    
      Study drug will be administered in the mid-vitreous by injection. Patients will be enrolled
      into the cohorts in a sequential dose/time-escalating fashion. To ensure that enrolment is
      evenly balanced across eligible conditions, enrolment of any specific underlying disease type
      into any cohort will be capped at five (5) patients.
    
  